Beneficient

Beneficient amended its Standby Equity Purchase Agreement (SEPA) with Yorkville, reducing the potential equity sale to $100.0 million. Concurrently, the company issued $4.0 million in convertible promissory notes to Yorkville, receiving $3.6 million in gross proceeds after a 5% original issue discount. These notes mature on June 30, 2027, bear 5.0% interest, and are convertible into Class A common stock at a variable price with a floor of $0.89 per share.

Beneficient filed an S-1 registration statement for the resale of up to 55,671,296 shares of Class A common stock by various selling holders. These shares include those from an Amended and Restated Standby Equity Purchase Agreement (A&R SEPA) with Yorkville, which reduced the commitment to $100 million and provided $4.0 million in promissory notes, as well as shares convertible from various Series B preferred stock issuances. The company also disclosed substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, existing defaults, and an arbitration award.

Beneficient announced the closing of a $7.44 million GP primary capital transaction with Quartus AI Fund II LP, an AI-focused investment fund. In exchange, Beneficient issued 744,455 shares of Series B-11 Resettable Convertible Preferred Stock, convertible into Class A Common Stock at an initial price of $3.6514 per share. This transaction is expected to increase the collateral for the company's ExAlt loan portfolio and add approximately $7.44 million to tangible book value attributable to stockholders, contributing to a fiscal year-to-date total of $17.2 million from such transactions.

Beneficient announced it has closed a $7.44 million primary capital commitment in Quartus AI Fund II LP, an AI-focused fund managed by Quartus Capital Partners LLC. This marks Beneficient's second GP primary capital transaction this year with Quartus, expanding its GP Primary Commitment Program. The investment, made in exchange for convertible preferred stock, is expected to increase collateral for Beneficient's ExAlt loan portfolio and add $7.44 million to tangible book value attributable to stockholders. The fund targets growth stage AI companies across various high-growth sectors.

Beneficient amended its Standby Equity Purchase Agreement (SEPA) with Yorkville, reducing the potential equity sales from $250.0 million to $100.0 million. Concurrently, the company secured a $4.0 million advance through convertible promissory notes from Yorkville. The first tranche of $2.0 million, with a 5% original issue discount, resulted in gross proceeds of approximately $1.8 million and was received on July 1, 2026. These notes mature on June 30, 2027, bear 5.0% interest, and are convertible into Class A common stock with a variable conversion price and a floor of $0.89 per share.

Beneficient's 10-K filing reveals substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows, and existing debt defaults. The company also disclosed two recent reverse stock splits (80-to-1 in 2024 and 8-to-1 in 2025) to maintain its Nasdaq listing. Despite these challenges, Beneficient outlined its business strategy, including a Board-approved ExchangeTrust Product Plan to complete up to $5 billion in fiduciary financings for alternative assets.

Beneficient's CEO James Silk announced significant progress in a letter to shareholders, including his permanent appointment as CEO. The company has resolved GWG litigation, regained Nasdaq compliance, and strengthened its balance sheet through $51.5 million in asset sales and repayment of the HH-BDH Credit Agreement principal. Beneficient also completed $14.9 million in GP Primary Commitment transactions and commercialized new AI-powered collateral management services, signaling a strategic shift towards a broader operating platform with multiple revenue streams.

Beneficient reported a significant net loss of $(87.4) million for fiscal year 2026 and $(38.6) million for the fourth quarter, attributable to common shareholders. Despite the financial downturn, the company highlighted substantial progress in addressing legacy issues, including resolving GWG Holdings litigation and regaining Nasdaq compliance. Beneficient also generated over $50 million from asset sales, fully paid off its HH-BDH Credit Agreement, and appointed James Silk as permanent CEO, signaling a focus on strengthening its foundation and pursuing new growth opportunities.

Beneficient reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighting significant progress in addressing legacy issues and strengthening its financial position. The company resolved GWG Holdings litigation, regained Nasdaq compliance, and fully repaid its HH-BDH Credit Agreement principal. James Silk, who had been Interim CEO, was officially appointed Chief Executive Officer, and the company secured its first collateral management services engagement.

Beneficient announced its first engagement to provide collateral management services for a third-party Texas state-chartered bank. This marks the commercial deployment of its new service offering, which will provide ongoing collateral monitoring and reporting for alternative assets pledged in a secured lending transaction. The company expects this engagement to generate recurring annual fee revenue and views it as a significant milestone validating its expertise and reporting capabilities for financial institutions.